Cartesian Therapeutics Depreciation & Amortization Growth & History (RNAC)

Cartesian Therapeutics's depreciation and amortization was $3.2M for fiscal 2025.

View full Cartesian Therapeutics company overview

Cartesian Therapeutics annual depreciation and amortization history

Cartesian Therapeutics annual depreciation and amortization

Fiscal yearPeriod endedDepreciation and amortizationChangeGrowth
20252025-12-31$3.2M−$459,000−12.62%
20242024-12-31$3.6M$1.2M+48.21%
20232023-12-31$2.5M$417,000+20.47%
20222022-12-31$2.0M$318,000+18.50%
20212021-12-31$1.7M−$8,000−0.46%
20202020-12-31$1.7M−$274,000−13.69%
20192019-12-31$2.0M$1.0M+100.10%
20182018-12-31$1.0M$250,000+33.33%
20172017-12-31$750,000−$52,000−6.48%
20162016-12-31$802,000−$242,000−23.18%
20152015-12-31$1.0M$180,000+20.83%
20142014-12-31$864,000

Cartesian Therapeutics depreciation and amortization trends

Over the last five fiscal years, Cartesian Therapeutics's depreciation and amortization increased from $1.7M to $3.2M, a change of $1.5M. The latest reported quarter, Q2 2026, shows $1.0M.

About the metric

What depreciation and amortization mean

Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.

Calculation and source

Reported depreciation and amortization

TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Cartesian Therapeutics source filings ↗

Community posts

It’s quiet here.

No posts about RNAC yet. Start the conversation.

Write the first post